Business
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances CINCINNATI, Ohio, May 13, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today provided an update on the Q1 2026 operational progress of its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), developer of Proclarix®, a CE-IVD certified diagnostic bl
About this update from Onconetix, Inc.
[{"type":"image","alt":"Onconetix, Inc.","displaySize":"","headline":null,"caption":"Onconetix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/b55f7083e8df04f051b0c99ec61411e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QZocyxD0u1tAwi7duLOZNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b55f7083e8df04f051b0c99ec61411e2","width":300,"height":105},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/QZocyxD0u1tAwi7duLOZNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b55f7083e8df04f051b0c99ec61411e2","width":300,"height":105}},"lazy":false},{"type":"text","content":"New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances","length":207,"tagName":"p"},{"type":"text","content":"CINCINNATI, Ohio, May 13, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today provided an update on the Q1 2026 operational progress of its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), developer of Proclarix®, a CE-IVD certified diagnostic blood test used in combination with PSA (prostate-specific antigen) to identify clinically significant prostate cancer (“csPCa”).","length":419,"tagName":"p"},{"type":"text","content":"Prostate cancer is the most frequently diagnosed male cancer in most countries globally and represents a significant burden to patients and healthcare systems. Proclarix® is designed to support clinicians in distinguishing clinically significant from clinically insignificant prostate cancer at an early stage, reducing unnecessary biopsies and overdiagnosis.","length":359,"tagName":"p"},{"type":"text","content":"New Peer-Reviewed Clinical Publications","length":39,"tagName":"p"},{"type":"text","content":"Two new peer-reviewed scientific publications from a recent clinical study conducted in Denmark further reinforce the clinical utility of Proclarix®.","length":149,"tagName":"p"},{"type":"text","content":"The first paper, by Schiess et al., has been accepted for publication in BMC Cancer, a renowned open-access oncology research journal. The study evaluated Proclari...